Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Monash University
With
National Health and Medical Research Council, Australia
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Capable of providing informed consent and willing to adhere to all protocol requirements
patients aged \> or equal to 40 years
Histologically confirmed melanoma of any stage planned for, commenced, or completed treatment with ICI
having acceptable imaging quality deemed by the core laboratory
Investigator believes that the participant is willing to adhere to all protocol requirements, including returning for follow up CTCA.
You may not be if
Known clinically manifest cardiovascular disease
Female participants must not be pregnant, breastfeeding or plan to become pregnant during the study.
Estimated glomerular filtration rate of \<45 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration equation
Severe liver disease or cirrhosis
History of any other malignancy within the past 5 years in addition to melanoma with the exception of non-melanoma skin cancers
Prognostic factors associated with an expected survival less than 18 months at Investigators' discretion (e.g. unresectable brain metastases)
Evidence of any other clinically significant non-cardiac disease or condition that, in the opinion of the Investigator, would preclude participation in the study
Major allergy to iodine
Participation in another clinical trial that does not allow participation in multiple trials at the same time
Clareo Health | Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
